KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Regeneron Pharmaceuticals (REGN) Notes Payables: 2014-2020

Regeneron Pharmaceuticals' Notes Payables was N/A to $1.5 billion in Q2 2020 from the same period last year, while for Jun 2020 it was $1.5 billion, marking a year-over-year change of. This contributed to the annual value of $1.6 million for FY2015, which is 78.67% down from last year.
As of Q2 2020, Regeneron Pharmaceuticals' Notes Payables stood at $1.5 billion, which was up 93,650.00% from $1.6 million recorded in Q4 2015.
Regeneron Pharmaceuticals' 5-year Notes Payables high stood at $1.5 billion for Q2 2020, and its period low was $1.5 billion during Q2 2020.
In the last 1 years, Regeneron Pharmaceuticals' Notes Payables had a median value of $1.5 billion in 2020 and averaged $1.5 billion.